KAM
Krensavage Asset Management Portfolio holdings
AUM
$189M
This Quarter Return
+2.46%
1 Year Return
+19.71%
3 Year Return
+56.44%
5 Year Return
+120.01%
10 Year Return
+215.64%
AUM
$316M
AUM Growth
+$316M
(-4.1%)
Cap. Flow
-$8.07M
Cap. Flow
% of AUM
-2.56%
Top 10 Holdings %
Top 10 Hldgs %
98.55%
Holding
12
New
–
Increased
6
Reduced
6
Closed
–
Top Buys
| 1 |
Enanta Pharmaceuticals
ENTA
|
$1.8M |
| 2 |
Embecta
EMBC
|
$188K |
| 3 |
United Therapeutics
UTHR
|
$134K |
| 4 |
TARO
Taro Pharmaceutical Industries Ltd.
TARO
|
$44.4K |
| 5 |
Cardinal Health
CAH
|
$41.2K |
Top Sells
| 1 |
Alkermes
ALKS
|
$9.15M |
| 2 |
Kodiak Sciences
KOD
|
$793K |
| 3 |
Regeneron Pharmaceuticals
REGN
|
$216K |
| 4 |
Biogen
BIIB
|
$85.5K |
| 5 |
Exelixis
EXEL
|
$41.4K |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Biogen
BIIB
$19.4B
| $50.4M | 15.96% | 176,826 -300 | -0.2% | -$85.5K |
|
|
2
United Therapeutics
UTHR
$13.8B
| $44.7M | 14.18% | 202,715 +605 | +0.3% | +$134K |
|
|
3
Regeneron Pharmaceuticals
REGN
$61.5B
| $42.5M | 13.47% | 59,188 -300 | -0.5% | -$216K |
|
|
4
Exelixis
EXEL
$10.1B
| $40.8M | 12.92% | 2,133,703 -2,165 | -0.1% | -$41.4K |
|
|
5
Alkermes
ALKS
$4.78B
| $34.5M | 10.94% | 1,103,451 -292,346 | -21% | -$9.15M |
|
|
6
Cardinal Health
CAH
$35.5B
| $33.5M | 10.6% | 353,714 +436 | +0.1% | +$41.2K |
|
|
TARO
7
DELISTED
Taro Pharmaceutical Industries Ltd.
TARO
| $24.4M | 7.73% | 643,080 +1,170 | +0.2% | +$44.4K |
|
|
8
Embecta
EMBC
$847M
| $23.1M | 7.33% | 1,070,810 +8,687 | +0.8% | +$188K |
|
|
9
Enanta Pharmaceuticals
ENTA
$180M
| $14.7M | 4.66% | 687,613 +84,312 | +14% | +$1.8M |
|
10
Vanda Pharmaceuticals
VNDA
$279M
| $2.39M | 0.76% | 362,951 +1,391 | +0.4% | +$9.17K |
|
|
11
Kodiak Sciences
KOD
$478M
| $2.38M | 0.75% | 344,634 -114,855 | -25% | -$793K |
|
|
EGRX
12
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
| $2.21M | 0.7% | 113,437 -300 | -0.3% | -$5.83K |
|